<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81903">
  <stage>Registered</stage>
  <submitdate>8/03/2007</submitdate>
  <approvaldate>9/03/2007</approvaldate>
  <actrnumber>ACTRN12607000163404</actrnumber>
  <trial_identification>
    <studytitle>Protein intake metabolic effects study</studytitle>
    <scientifictitle>A randomised controlled study to evaluate the effects of whey protein supplementation on bone structure, muscle mass, renal function, cardiovascular risk factors and body composition in elderly women</scientifictitle>
    <utrn />
    <trialacronym>PIMES</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Bone structure of elderly healthy women</healthcondition>
    <healthcondition>Muscle mass of elderly healthy women</healthcondition>
    <healthcondition>Renal function of elderly healthy women</healthcondition>
    <healthcondition>Cardiovascular risk factors of elderly healthy women</healthcondition>
    <healthcondition>Body composition of elderly healthy women</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Normal musculoskeletal and cartilage development and function</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Normal development and function of the cardiovascular system</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Normal development and function of male and female renal and urogenital system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A two-year randomised double-blind dietary intervention study of daily 30 g whey protein in the form of milk beverage drink versus placebo drink. All participants receive 600 mg calcium per day from the drink.</interventions>
    <comparator>Placebo drink</comparator>
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>1) Bone structure of total body, hip, spine, forearm and tibia as measured by Dual Energy X-ray Absorptiometry and Quantitative Computed Tomography (QCT).</outcome>
      <timepoint>Measurements will be made at baseline, 1 and 2 years, except QCT of hip and spine, which will only be made at baseline and 2 years.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>2) Body composition using anthropometry (height, weight, waist circumference, waist and hip ratio, skin fold), Dual Energy X-ray Absorptiometry body composition and CT abdominal fat.</outcome>
      <timepoint>Measurements will be made at baseline, 1 and 2 years, except QCT of hip and spine, which will only be made at baseline and 2 years.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>1) Hand grip strength and lower limb muscle strength as assessed by hand dynamometer and strain gauge.</outcome>
      <timepoint>Measurements will be made at baseline, 1 and 2 years.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>2) Mobility function as assessed by the Timed Up and Go test.</outcome>
      <timepoint>Measurements will be made at baseline, 1 and 2 years.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>3) Insulin like growth factor I (IGF-I).</outcome>
      <timepoint>Measurements will be made at baseline, 1 and 2 years.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>4) Biochemical markers of bone turnover.</outcome>
      <timepoint>Measurements will be made at baseline, 1 and 2 years.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>5) Renal function as assessed by glomerular filtration rate </outcome>
      <timepoint>Measurements will be made at baseline, 1 and 2 years.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>6) Risk factors of cardiovascular diseases (blood pressure, blood profiles of lipids and glucose, serum c-reactive protein, apolipoprotein E and homocystine). </outcome>
      <timepoint>Measurements will be made at baseline, 1 and 2 years.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Able to comply with the requirements of the protocol.</inclusivecriteria>
    <inclusiveminage>70</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria> Participation in another clinical trial during the last 12 weeks  Previous osteoporotic fracture Currently or within last year taking medication for osteoporosis apart from calcium or vitamin D  Taking steroid tablets (eg Cortisone) in the past 3 months or have taken more than 7 g in total Metabolic bone disease apart from osteoporosis Total hip bone density more than 2SD below the mean for their age Lactose intolerance or do not like milk products High protein intake (more than 1.5 g/kg body weight per day) Cognitive impairment (Mini Mental Sate score &lt; 24) Body mass index &gt; 35 kg/cm2 Bowel surgery or difficulty absorbing food  Coeliac disease Hepatic insufficiency or renal insufficiency   Participants who, in the opinion of the investigator are not likely to complete the study for any reason.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Subject numbers will be allocated by personnel having no contact with study participants</concealment>
    <sequence>Computer-generated randomisation sequence</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>The study participants, therapists, assessors and data analysts will remain blinded to the treatment code until all the data be entered, evaluated for accuracy and the a-priori hypotheses reviewed</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/04/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>220</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>A Professor RL Prince</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Australian National Health and Medical Research Council</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>The University of Western Australia and</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname> the Sir Charles Gairdner Hospital</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a randomised controlled study to evaluate the effects of daily 30 g whey protein supplementation on bone structure, muscle mass and strength, renal function, cardiovascular risk factors and body composition in women aged 70-80 years at baseline.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Sir Charles Gairdner Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>21/02/2007</ethicapprovaldate>
      <hrec>2006-181</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>A Professor Richard Prince</name>
      <address>Bone and Calcium Research Group
School of Medicine and Pharmacology
University of Western Australia
Department of Endocrinology and Diabetes
1st Floor C Block
Sir Charles Gairdner Hospital
Hospital Ave
Nedlands 6009</address>
      <phone>61 8 9346 4111</phone>
      <fax>61 8 9346 2733</fax>
      <email>rlprince@cyllene.uwa.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>A Professor Richard Prince</name>
      <address>Bone and Calcium Research Group
School of Medicine and Pharmacology
University of Western Australia
Department of Endocrinology and Diabetes
1st Floor C Block
Sir Charles Gairdner Hospital
Hospital Ave, Nedlands 6009</address>
      <phone>61 8 9346 4111</phone>
      <fax>61 8 9346 2733</fax>
      <email>rlprince@cyllene.uwa.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>